210 related articles for article (PubMed ID: 23952890)
1. Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?
Nocente R; Vitali M; Balducci G; Enea D; Kranzler HR; Ceccanti M
Am J Addict; 2013; 22(5):453-9. PubMed ID: 23952890
[TBL] [Abstract][Full Text] [Related]
2. Varenicline in the treatment of alcohol use disorders.
Erwin BL; Slaton RM
Ann Pharmacother; 2014 Nov; 48(11):1445-55. PubMed ID: 25095786
[TBL] [Abstract][Full Text] [Related]
3. Varenicline: for smoking cessation.
Rao J; Shankar PK
Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of varenicline for smoking cessation.
Hays JT; Ebbert JO; Sood A
Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
[TBL] [Abstract][Full Text] [Related]
5. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.
Crunelle CL; Miller ML; Booij J; van den Brink W
Eur Neuropsychopharmacol; 2010 Feb; 20(2):69-79. PubMed ID: 19959340
[TBL] [Abstract][Full Text] [Related]
6. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
Foulds J
Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
[TBL] [Abstract][Full Text] [Related]
7. [New drugs; varenicline].
van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness and safety of varenicline for smoking cessation].
Christalla P; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
[TBL] [Abstract][Full Text] [Related]
9. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.
Rollema H; Coe JW; Chambers LK; Hurst RS; Stahl SM; Williams KE
Trends Pharmacol Sci; 2007 Jul; 28(7):316-25. PubMed ID: 17573127
[TBL] [Abstract][Full Text] [Related]
10. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial.
Meszaros ZS; Abdul-Malak Y; Dimmock JA; Wang D; Ajagbe TO; Batki SL
J Clin Psychopharmacol; 2013 Apr; 33(2):243-7. PubMed ID: 23422399
[TBL] [Abstract][Full Text] [Related]
11. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
Raybuck JD; Portugal GS; Lerman C; Gould TJ
Behav Neurosci; 2008 Oct; 122(5):1166-71. PubMed ID: 18823172
[TBL] [Abstract][Full Text] [Related]
12. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
Steensland P; Simms JA; Holgate J; Richards JK; Bartlett SE
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12518-23. PubMed ID: 17626178
[TBL] [Abstract][Full Text] [Related]
13. Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.
Hussmann GP; DeDominicis KE; Turner JR; Yasuda RP; Klehm J; Forcelli PA; Xiao Y; Richardson JR; Sahibzada N; Wolfe BB; Lindstrom J; Blendy JA; Kellar KJ
J Neurochem; 2014 May; 129(4):721-31. PubMed ID: 24422997
[TBL] [Abstract][Full Text] [Related]
14. Varenicline reduces alcohol self-administration in heavy-drinking smokers.
McKee SA; Harrison EL; O'Malley SS; Krishnan-Sarin S; Shi J; Tetrault JM; Picciotto MR; Petrakis IL; Estevez N; Balchunas E
Biol Psychiatry; 2009 Jul; 66(2):185-90. PubMed ID: 19249750
[TBL] [Abstract][Full Text] [Related]
15. [New tobacco dependence drug: Varenicline, partial agonist of alpha4beta2 acetylcholine-nicotine receptors].
Králíková E
Cas Lek Cesk; 2006; 145(11):832-4. PubMed ID: 17168413
[TBL] [Abstract][Full Text] [Related]
16. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.
Chatterjee S; Bartlett SE
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):60-76. PubMed ID: 20201817
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
19. [On oral medications, especially varenicline].
Kurioka N
Nihon Rinsho; 2013 Mar; 71(3):487-92. PubMed ID: 23631241
[TBL] [Abstract][Full Text] [Related]
20. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study.
Hays JT; Croghan IT; Schroeder DR; Ebbert JO; Hurt RD
J Subst Abuse Treat; 2011 Jan; 40(1):102-7. PubMed ID: 20947286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
